B+
Bull case
20%
Probability
Target price
$28.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
TCMD
TactileCNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
Q2 revenue grew 9% to $85.7 million, gross margin reached 76%, and adjusted EBITDA rose to $11.4 million. Sustained lymphedema growth and an AffloVest ordering recovery could support the maintained EBITDA outlook.
Posture
Mixed
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-11-02 · AMC.
What can break
AffloVest distributor inventory may remain elevated longer than management expects, pressuring airway-clearance orders. [#SEC-8K-2026-08-10]
Momentum
30
Value
63
Sentiment
45
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $22.00 · Bull $28.00 · Bear $15.00Analysis 2026-10-02; returns require an exact persisted reference.
Earnings
2026-11-02 · AMC
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-27
Investment thesis
As of 2026-10-27
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-27. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $37.67
Why
Momentum30 · Δ7d -4.4
Value63 · Δ7d -0.1
Sentiment45 · Δ7d -4.3
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-11-02 · AMC.
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • AffloVest distributor inventory may remain elevated longer than management expects, pressuring airway-clearance orders. [#SEC-8K-2026-08-10]
- • LymphaTech integration and newer-product distribution have not yet demonstrated a quantified incremental sales contribution in the supplied evidence. [#SEC-8K-2026-08-10]
- • The revenue-guidance ceiling was reduced by $2 million because the company expects more conservative airway-clearance ordering.
Catalyst clock
2026-11-02 · AMC
Delivery against narrowed 2026 revenue guidance
Lead driver: Value · See fundamentals
Momentum
30
8% active weight
Current posture
7d trendSoftening
Δ7d
-4.4
Δ21d
+4.9
Value
63
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
45
45% active weight
Current posture
7d trendSoftening
Δ7d
-4.3
Δ21d
-12.8
Why this grade
Composite grade C. Momentum 29.7 / Value 63.2 / Sentiment 45.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-02. Scenario method
Most likely
B
Base case
60%
Probability
Target price
$22.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$531.42M
Beta
0.96
Shares Out
22.65M
P/E (TTM)
38.8
P/S (TTM)
2.16
P/FCF (TTM)
17.08
Rev YoY
+8.6%
EPS YoY
+143.9%
Gross Margin
+76.1%
Op Margin
+10.0%
Net Debt
-$67.49M
Current Ratio
4.12
As of 2026-10-27 • Updated nightlySource: Internal modelMethods & Data